nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—ABCB1—Ezetimibe—atherosclerosis	0.146	0.267	CbGbCtD
Nadolol—ABCB1—Simvastatin—atherosclerosis	0.136	0.248	CbGbCtD
Nadolol—ABCB1—Pravastatin—atherosclerosis	0.133	0.243	CbGbCtD
Nadolol—ABCB1—Lovastatin—atherosclerosis	0.133	0.243	CbGbCtD
Nadolol—Arterial thrombosis—Niacin—atherosclerosis	0.014	0.0423	CcSEcCtD
Nadolol—Ache—Lovastatin—atherosclerosis	0.00949	0.0288	CcSEcCtD
Nadolol—Ache—Simvastatin—atherosclerosis	0.00887	0.0269	CcSEcCtD
Nadolol—Ache—Pravastatin—atherosclerosis	0.00802	0.0243	CcSEcCtD
Nadolol—Sleep disturbance—Simvastatin—atherosclerosis	0.00731	0.0222	CcSEcCtD
Nadolol—Sleep disturbance—Pravastatin—atherosclerosis	0.00661	0.02	CcSEcCtD
Nadolol—Hepatic enzyme increased—Rosuvastatin—atherosclerosis	0.00546	0.0166	CcSEcCtD
Nadolol—Laryngospasm—Niacin—atherosclerosis	0.00504	0.0153	CcSEcCtD
Nadolol—Sleep disorder—Rosuvastatin—atherosclerosis	0.00433	0.0131	CcSEcCtD
Nadolol—Amnesia—Rosuvastatin—atherosclerosis	0.00399	0.0121	CcSEcCtD
Nadolol—Fluid retention—Niacin—atherosclerosis	0.00357	0.0108	CcSEcCtD
Nadolol—Sleep disorder—Simvastatin—atherosclerosis	0.00344	0.0104	CcSEcCtD
Nadolol—Amnesia—Lovastatin—atherosclerosis	0.00338	0.0103	CcSEcCtD
Nadolol—Amnesia—Ezetimibe—atherosclerosis	0.00332	0.0101	CcSEcCtD
Nadolol—Amnesia—Simvastatin—atherosclerosis	0.00317	0.0096	CcSEcCtD
Nadolol—Sleep disorder—Pravastatin—atherosclerosis	0.00311	0.00942	CcSEcCtD
Nadolol—Depression—Rosuvastatin—atherosclerosis	0.00288	0.00874	CcSEcCtD
Nadolol—Amnesia—Pravastatin—atherosclerosis	0.00286	0.00868	CcSEcCtD
Nadolol—Gastritis—Ezetimibe—atherosclerosis	0.00276	0.00837	CcSEcCtD
Nadolol—Disturbance in sexual arousal—Niacin—atherosclerosis	0.00271	0.00821	CcSEcCtD
Nadolol—Diplopia—Pravastatin—atherosclerosis	0.00269	0.00815	CcSEcCtD
Nadolol—Affect lability—Pravastatin—atherosclerosis	0.00265	0.00802	CcSEcCtD
Nadolol—Abdominal discomfort—Lovastatin—atherosclerosis	0.00263	0.00799	CcSEcCtD
Nadolol—Gastritis—Simvastatin—atherosclerosis	0.00263	0.00798	CcSEcCtD
Nadolol—Mood swings—Pravastatin—atherosclerosis	0.00255	0.00772	CcSEcCtD
Nadolol—Erectile dysfunction—Lovastatin—atherosclerosis	0.00253	0.00767	CcSEcCtD
Nadolol—Dry skin—Niacin—atherosclerosis	0.0025	0.00759	CcSEcCtD
Nadolol—Erectile dysfunction—Ezetimibe—atherosclerosis	0.00248	0.00753	CcSEcCtD
Nadolol—Dry skin—Pravastatin—atherosclerosis	0.00246	0.00747	CcSEcCtD
Nadolol—Abdominal discomfort—Simvastatin—atherosclerosis	0.00246	0.00747	CcSEcCtD
Nadolol—Abdominal distension—Niacin—atherosclerosis	0.00238	0.0072	CcSEcCtD
Nadolol—Erectile dysfunction—Simvastatin—atherosclerosis	0.00237	0.00718	CcSEcCtD
Nadolol—Abdominal distension—Pravastatin—atherosclerosis	0.00234	0.00709	CcSEcCtD
Nadolol—Depression—Simvastatin—atherosclerosis	0.00229	0.00693	CcSEcCtD
Nadolol—Flatulence—Rosuvastatin—atherosclerosis	0.00223	0.00675	CcSEcCtD
Nadolol—Erectile dysfunction—Niacin—atherosclerosis	0.00217	0.00659	CcSEcCtD
Nadolol—Erectile dysfunction—Pravastatin—atherosclerosis	0.00214	0.00649	CcSEcCtD
Nadolol—Weight increased—Pravastatin—atherosclerosis	0.00211	0.00641	CcSEcCtD
Nadolol—Depression—Pravastatin—atherosclerosis	0.00207	0.00626	CcSEcCtD
Nadolol—Sweating—Niacin—atherosclerosis	0.00202	0.00612	CcSEcCtD
Nadolol—Cough—Rosuvastatin—atherosclerosis	0.00197	0.00598	CcSEcCtD
Nadolol—Alopecia—Lovastatin—atherosclerosis	0.00194	0.00589	CcSEcCtD
Nadolol—Alopecia—Ezetimibe—atherosclerosis	0.00191	0.00578	CcSEcCtD
Nadolol—Flatulence—Lovastatin—atherosclerosis	0.00189	0.00572	CcSEcCtD
Nadolol—Flatulence—Ezetimibe—atherosclerosis	0.00185	0.00561	CcSEcCtD
Nadolol—Visual impairment—Niacin—atherosclerosis	0.00182	0.00552	CcSEcCtD
Nadolol—Alopecia—Simvastatin—atherosclerosis	0.00182	0.00551	CcSEcCtD
Nadolol—Vision blurred—Lovastatin—atherosclerosis	0.0018	0.00547	CcSEcCtD
Nadolol—Visual impairment—Pravastatin—atherosclerosis	0.00179	0.00543	CcSEcCtD
Nadolol—Flatulence—Simvastatin—atherosclerosis	0.00176	0.00535	CcSEcCtD
Nadolol—Tinnitus—Niacin—atherosclerosis	0.00176	0.00534	CcSEcCtD
Nadolol—Tinnitus—Pravastatin—atherosclerosis	0.00173	0.00526	CcSEcCtD
Nadolol—Vision blurred—Simvastatin—atherosclerosis	0.00169	0.00512	CcSEcCtD
Nadolol—Alopecia—Niacin—atherosclerosis	0.00167	0.00506	CcSEcCtD
Nadolol—Insomnia—Rosuvastatin—atherosclerosis	0.00167	0.00506	CcSEcCtD
Nadolol—Paraesthesia—Rosuvastatin—atherosclerosis	0.00166	0.00502	CcSEcCtD
Nadolol—Alopecia—Pravastatin—atherosclerosis	0.00164	0.00498	CcSEcCtD
Nadolol—Cough—Ezetimibe—atherosclerosis	0.00164	0.00497	CcSEcCtD
Nadolol—Chest pain—Lovastatin—atherosclerosis	0.00163	0.00494	CcSEcCtD
Nadolol—Dyspepsia—Rosuvastatin—atherosclerosis	0.00162	0.00492	CcSEcCtD
Nadolol—Hypertension—Ezetimibe—atherosclerosis	0.00162	0.00492	CcSEcCtD
Nadolol—Flatulence—Niacin—atherosclerosis	0.00162	0.00491	CcSEcCtD
Nadolol—Chest pain—Ezetimibe—atherosclerosis	0.0016	0.00485	CcSEcCtD
Nadolol—Flatulence—Pravastatin—atherosclerosis	0.0016	0.00484	CcSEcCtD
Nadolol—Dry mouth—Lovastatin—atherosclerosis	0.00159	0.00483	CcSEcCtD
Nadolol—Pain—Rosuvastatin—atherosclerosis	0.00158	0.00478	CcSEcCtD
Nadolol—Constipation—Rosuvastatin—atherosclerosis	0.00158	0.00478	CcSEcCtD
Nadolol—Dry mouth—Ezetimibe—atherosclerosis	0.00156	0.00474	CcSEcCtD
Nadolol—Vision blurred—Niacin—atherosclerosis	0.00155	0.0047	CcSEcCtD
Nadolol—Vision blurred—Pravastatin—atherosclerosis	0.00153	0.00463	CcSEcCtD
Nadolol—Chest pain—Simvastatin—atherosclerosis	0.00152	0.00462	CcSEcCtD
Nadolol—Anorexia—Lovastatin—atherosclerosis	0.00149	0.00452	CcSEcCtD
Nadolol—Syncope—Niacin—atherosclerosis	0.00147	0.00447	CcSEcCtD
Nadolol—Oedema—Simvastatin—atherosclerosis	0.00146	0.00443	CcSEcCtD
Nadolol—Loss of consciousness—Niacin—atherosclerosis	0.00145	0.00438	CcSEcCtD
Nadolol—Cough—Niacin—atherosclerosis	0.00144	0.00435	CcSEcCtD
Nadolol—Insomnia—Lovastatin—atherosclerosis	0.00141	0.00429	CcSEcCtD
Nadolol—Cough—Pravastatin—atherosclerosis	0.00141	0.00428	CcSEcCtD
Nadolol—Paraesthesia—Lovastatin—atherosclerosis	0.0014	0.00425	CcSEcCtD
Nadolol—Hypertension—Pravastatin—atherosclerosis	0.0014	0.00424	CcSEcCtD
Nadolol—Anorexia—Simvastatin—atherosclerosis	0.00139	0.00422	CcSEcCtD
Nadolol—Dyspnoea—Lovastatin—atherosclerosis	0.00139	0.00422	CcSEcCtD
Nadolol—Insomnia—Ezetimibe—atherosclerosis	0.00139	0.0042	CcSEcCtD
Nadolol—Chest pain—Pravastatin—atherosclerosis	0.00138	0.00418	CcSEcCtD
Nadolol—Paraesthesia—Ezetimibe—atherosclerosis	0.00138	0.00417	CcSEcCtD
Nadolol—Dyspepsia—Lovastatin—atherosclerosis	0.00138	0.00417	CcSEcCtD
Nadolol—Dry mouth—Niacin—atherosclerosis	0.00137	0.00415	CcSEcCtD
Nadolol—Dyspnoea—Ezetimibe—atherosclerosis	0.00137	0.00414	CcSEcCtD
Nadolol—Decreased appetite—Lovastatin—atherosclerosis	0.00136	0.00412	CcSEcCtD
Nadolol—Dyspepsia—Ezetimibe—atherosclerosis	0.00135	0.00409	CcSEcCtD
Nadolol—Fatigue—Lovastatin—atherosclerosis	0.00135	0.00408	CcSEcCtD
Nadolol—Oedema—Niacin—atherosclerosis	0.00134	0.00407	CcSEcCtD
Nadolol—Constipation—Lovastatin—atherosclerosis	0.00134	0.00405	CcSEcCtD
Nadolol—Pain—Lovastatin—atherosclerosis	0.00134	0.00405	CcSEcCtD
Nadolol—Decreased appetite—Ezetimibe—atherosclerosis	0.00133	0.00404	CcSEcCtD
Nadolol—Asthenia—Rosuvastatin—atherosclerosis	0.00132	0.00401	CcSEcCtD
Nadolol—Insomnia—Simvastatin—atherosclerosis	0.00132	0.00401	CcSEcCtD
Nadolol—Oedema—Pravastatin—atherosclerosis	0.00132	0.00401	CcSEcCtD
Nadolol—Fatigue—Ezetimibe—atherosclerosis	0.00132	0.00401	CcSEcCtD
Nadolol—Shock—Niacin—atherosclerosis	0.00132	0.004	CcSEcCtD
Nadolol—Paraesthesia—Simvastatin—atherosclerosis	0.00131	0.00398	CcSEcCtD
Nadolol—Constipation—Ezetimibe—atherosclerosis	0.00131	0.00397	CcSEcCtD
Nadolol—Pain—Ezetimibe—atherosclerosis	0.00131	0.00397	CcSEcCtD
Nadolol—Pruritus—Rosuvastatin—atherosclerosis	0.0013	0.00396	CcSEcCtD
Nadolol—Dyspnoea—Simvastatin—atherosclerosis	0.0013	0.00395	CcSEcCtD
Nadolol—Hyperhidrosis—Niacin—atherosclerosis	0.0013	0.00393	CcSEcCtD
Nadolol—Dyspepsia—Simvastatin—atherosclerosis	0.00129	0.0039	CcSEcCtD
Nadolol—Anorexia—Niacin—atherosclerosis	0.00128	0.00388	CcSEcCtD
Nadolol—Hyperhidrosis—Pravastatin—atherosclerosis	0.00128	0.00387	CcSEcCtD
Nadolol—Decreased appetite—Simvastatin—atherosclerosis	0.00127	0.00385	CcSEcCtD
Nadolol—Diarrhoea—Rosuvastatin—atherosclerosis	0.00126	0.00383	CcSEcCtD
Nadolol—Fatigue—Simvastatin—atherosclerosis	0.00126	0.00382	CcSEcCtD
Nadolol—Anorexia—Pravastatin—atherosclerosis	0.00126	0.00382	CcSEcCtD
Nadolol—Hypotension—Niacin—atherosclerosis	0.00125	0.0038	CcSEcCtD
Nadolol—Constipation—Simvastatin—atherosclerosis	0.00125	0.00379	CcSEcCtD
Nadolol—Pain—Simvastatin—atherosclerosis	0.00125	0.00379	CcSEcCtD
Nadolol—Body temperature increased—Lovastatin—atherosclerosis	0.00124	0.00375	CcSEcCtD
Nadolol—Dizziness—Rosuvastatin—atherosclerosis	0.00122	0.0037	CcSEcCtD
Nadolol—Insomnia—Niacin—atherosclerosis	0.00121	0.00368	CcSEcCtD
Nadolol—Body temperature increased—Ezetimibe—atherosclerosis	0.00121	0.00367	CcSEcCtD
Nadolol—Paraesthesia—Niacin—atherosclerosis	0.00121	0.00365	CcSEcCtD
Nadolol—Dyspnoea—Niacin—atherosclerosis	0.0012	0.00363	CcSEcCtD
Nadolol—Insomnia—Pravastatin—atherosclerosis	0.0012	0.00362	CcSEcCtD
Nadolol—Paraesthesia—Pravastatin—atherosclerosis	0.00119	0.0036	CcSEcCtD
Nadolol—Dyspepsia—Niacin—atherosclerosis	0.00118	0.00358	CcSEcCtD
Nadolol—Dyspnoea—Pravastatin—atherosclerosis	0.00118	0.00357	CcSEcCtD
Nadolol—Decreased appetite—Niacin—atherosclerosis	0.00117	0.00354	CcSEcCtD
Nadolol—Dyspepsia—Pravastatin—atherosclerosis	0.00116	0.00353	CcSEcCtD
Nadolol—Rash—Rosuvastatin—atherosclerosis	0.00116	0.00353	CcSEcCtD
Nadolol—Dermatitis—Rosuvastatin—atherosclerosis	0.00116	0.00352	CcSEcCtD
Nadolol—Body temperature increased—Simvastatin—atherosclerosis	0.00116	0.0035	CcSEcCtD
Nadolol—Decreased appetite—Pravastatin—atherosclerosis	0.00115	0.00348	CcSEcCtD
Nadolol—Pain—Niacin—atherosclerosis	0.00115	0.00348	CcSEcCtD
Nadolol—Fatigue—Pravastatin—atherosclerosis	0.00114	0.00345	CcSEcCtD
Nadolol—Pain—Pravastatin—atherosclerosis	0.00113	0.00343	CcSEcCtD
Nadolol—Constipation—Pravastatin—atherosclerosis	0.00113	0.00343	CcSEcCtD
Nadolol—Asthenia—Lovastatin—atherosclerosis	0.00112	0.0034	CcSEcCtD
Nadolol—Pruritus—Lovastatin—atherosclerosis	0.00111	0.00335	CcSEcCtD
Nadolol—Asthenia—Ezetimibe—atherosclerosis	0.0011	0.00333	CcSEcCtD
Nadolol—Nausea—Rosuvastatin—atherosclerosis	0.0011	0.00332	CcSEcCtD
Nadolol—Pruritus—Ezetimibe—atherosclerosis	0.00108	0.00329	CcSEcCtD
Nadolol—Diarrhoea—Lovastatin—atherosclerosis	0.00107	0.00324	CcSEcCtD
Nadolol—Body temperature increased—Niacin—atherosclerosis	0.00106	0.00322	CcSEcCtD
Nadolol—Asthenia—Simvastatin—atherosclerosis	0.00105	0.00318	CcSEcCtD
Nadolol—Diarrhoea—Ezetimibe—atherosclerosis	0.00105	0.00318	CcSEcCtD
Nadolol—Body temperature increased—Pravastatin—atherosclerosis	0.00104	0.00317	CcSEcCtD
Nadolol—Pruritus—Simvastatin—atherosclerosis	0.00103	0.00314	CcSEcCtD
Nadolol—Dizziness—Lovastatin—atherosclerosis	0.00103	0.00313	CcSEcCtD
Nadolol—Dizziness—Ezetimibe—atherosclerosis	0.00101	0.00307	CcSEcCtD
Nadolol—Diarrhoea—Simvastatin—atherosclerosis	0.001	0.00303	CcSEcCtD
Nadolol—Vomiting—Lovastatin—atherosclerosis	0.000994	0.00301	CcSEcCtD
Nadolol—Rash—Lovastatin—atherosclerosis	0.000985	0.00299	CcSEcCtD
Nadolol—Dermatitis—Lovastatin—atherosclerosis	0.000984	0.00298	CcSEcCtD
Nadolol—Vomiting—Ezetimibe—atherosclerosis	0.000975	0.00295	CcSEcCtD
Nadolol—Dizziness—Simvastatin—atherosclerosis	0.000967	0.00293	CcSEcCtD
Nadolol—Rash—Ezetimibe—atherosclerosis	0.000966	0.00293	CcSEcCtD
Nadolol—Dermatitis—Ezetimibe—atherosclerosis	0.000966	0.00293	CcSEcCtD
Nadolol—Asthenia—Niacin—atherosclerosis	0.000963	0.00292	CcSEcCtD
Nadolol—Pruritus—Niacin—atherosclerosis	0.00095	0.00288	CcSEcCtD
Nadolol—Asthenia—Pravastatin—atherosclerosis	0.000948	0.00287	CcSEcCtD
Nadolol—Pruritus—Pravastatin—atherosclerosis	0.000935	0.00283	CcSEcCtD
Nadolol—Vomiting—Simvastatin—atherosclerosis	0.000929	0.00282	CcSEcCtD
Nadolol—Nausea—Lovastatin—atherosclerosis	0.000928	0.00281	CcSEcCtD
Nadolol—Rash—Simvastatin—atherosclerosis	0.000922	0.00279	CcSEcCtD
Nadolol—Dermatitis—Simvastatin—atherosclerosis	0.000921	0.00279	CcSEcCtD
Nadolol—Diarrhoea—Niacin—atherosclerosis	0.000918	0.00278	CcSEcCtD
Nadolol—Nausea—Ezetimibe—atherosclerosis	0.00091	0.00276	CcSEcCtD
Nadolol—Diarrhoea—Pravastatin—atherosclerosis	0.000904	0.00274	CcSEcCtD
Nadolol—Dizziness—Niacin—atherosclerosis	0.000888	0.00269	CcSEcCtD
Nadolol—Dizziness—Pravastatin—atherosclerosis	0.000874	0.00265	CcSEcCtD
Nadolol—Nausea—Simvastatin—atherosclerosis	0.000868	0.00263	CcSEcCtD
Nadolol—Vomiting—Niacin—atherosclerosis	0.000853	0.00259	CcSEcCtD
Nadolol—Rash—Niacin—atherosclerosis	0.000846	0.00257	CcSEcCtD
Nadolol—Dermatitis—Niacin—atherosclerosis	0.000845	0.00256	CcSEcCtD
Nadolol—Vomiting—Pravastatin—atherosclerosis	0.00084	0.00255	CcSEcCtD
Nadolol—Rash—Pravastatin—atherosclerosis	0.000833	0.00253	CcSEcCtD
Nadolol—Dermatitis—Pravastatin—atherosclerosis	0.000832	0.00252	CcSEcCtD
Nadolol—Nausea—Niacin—atherosclerosis	0.000797	0.00242	CcSEcCtD
Nadolol—Nausea—Pravastatin—atherosclerosis	0.000785	0.00238	CcSEcCtD
Nadolol—ADRB1—Signaling Pathways—UTS2—atherosclerosis	8.29e-05	0.000673	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—KNG1—atherosclerosis	8.28e-05	0.000672	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—AGTR1—atherosclerosis	8.27e-05	0.000671	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AGTR1—atherosclerosis	8.23e-05	0.000668	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—KNG1—atherosclerosis	8.14e-05	0.00066	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—UTS2—atherosclerosis	8.11e-05	0.000658	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—AGTR1—atherosclerosis	8.09e-05	0.000656	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CCL2—atherosclerosis	8.08e-05	0.000655	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PLG—atherosclerosis	8.02e-05	0.000651	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CASR—atherosclerosis	7.95e-05	0.000645	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CX3CR1—atherosclerosis	7.95e-05	0.000645	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CX3CL1—atherosclerosis	7.8e-05	0.000632	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CX3CR1—atherosclerosis	7.78e-05	0.000631	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CASR—atherosclerosis	7.78e-05	0.000631	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—EDN1—atherosclerosis	7.72e-05	0.000626	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—atherosclerosis	7.72e-05	0.000626	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CCL5—atherosclerosis	7.66e-05	0.000622	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CX3CL1—atherosclerosis	7.63e-05	0.000619	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SOCS3—atherosclerosis	7.6e-05	0.000616	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—EDN1—atherosclerosis	7.55e-05	0.000613	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CCL5—atherosclerosis	7.5e-05	0.000608	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—PLAT—atherosclerosis	7.43e-05	0.000603	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CNR2—atherosclerosis	7.39e-05	0.0006	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CXCL8—atherosclerosis	7.39e-05	0.000599	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—MMP3—atherosclerosis	7.37e-05	0.000598	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MMP3—atherosclerosis	7.34e-05	0.000595	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IGF2—atherosclerosis	7.31e-05	0.000593	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PRKCG—atherosclerosis	7.29e-05	0.000591	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CNR2—atherosclerosis	7.23e-05	0.000586	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CXCL8—atherosclerosis	7.22e-05	0.000586	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—MMP3—atherosclerosis	7.21e-05	0.000585	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PRKCG—atherosclerosis	7.13e-05	0.000578	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—APOB—atherosclerosis	7.09e-05	0.000575	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CXCL8—atherosclerosis	7.03e-05	0.00057	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—EDN1—atherosclerosis	7.01e-05	0.000569	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—EDN1—atherosclerosis	6.98e-05	0.000566	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CCL5—atherosclerosis	6.96e-05	0.000565	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCL5—atherosclerosis	6.93e-05	0.000562	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—EDN1—atherosclerosis	6.86e-05	0.000557	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CCL5—atherosclerosis	6.81e-05	0.000552	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ABCG1—atherosclerosis	6.8e-05	0.000552	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—LPL—atherosclerosis	6.77e-05	0.000549	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—atherosclerosis	6.7e-05	0.000543	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PRKCG—atherosclerosis	6.62e-05	0.000537	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—VWF—atherosclerosis	6.59e-05	0.000534	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PRKCG—atherosclerosis	6.58e-05	0.000534	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atherosclerosis	6.58e-05	0.000534	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—APOC3—atherosclerosis	6.55e-05	0.000531	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—LDLR—atherosclerosis	6.51e-05	0.000528	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PRKCG—atherosclerosis	6.47e-05	0.000525	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—VWF—atherosclerosis	6.44e-05	0.000523	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SPP1—atherosclerosis	6.41e-05	0.00052	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—AGT—atherosclerosis	6.41e-05	0.00052	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—APOC3—atherosclerosis	6.4e-05	0.000519	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—FABP4—atherosclerosis	6.4e-05	0.000519	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—LCAT—atherosclerosis	6.4e-05	0.000519	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CXCL8—atherosclerosis	6.39e-05	0.000518	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—LDLR—atherosclerosis	6.36e-05	0.000516	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCL3—atherosclerosis	6.35e-05	0.000516	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—PLG—atherosclerosis	6.32e-05	0.000513	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APOA4—atherosclerosis	6.28e-05	0.000509	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—AGT—atherosclerosis	6.27e-05	0.000509	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCL3—atherosclerosis	6.22e-05	0.000504	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP7A1—atherosclerosis	6.17e-05	0.0005	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NCF1—atherosclerosis	6.09e-05	0.000494	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—atherosclerosis	6.08e-05	0.000493	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NCF1—atherosclerosis	5.95e-05	0.000483	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PDGFB—atherosclerosis	5.93e-05	0.000481	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—F2—atherosclerosis	5.92e-05	0.000481	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—HMOX1—atherosclerosis	5.83e-05	0.000473	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—AGT—atherosclerosis	5.82e-05	0.000472	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—F2—atherosclerosis	5.79e-05	0.00047	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AGT—atherosclerosis	5.79e-05	0.00047	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—atherosclerosis	5.75e-05	0.000467	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCR2—atherosclerosis	5.75e-05	0.000466	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EDNRA—atherosclerosis	5.75e-05	0.000466	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CYBA—atherosclerosis	5.72e-05	0.000464	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP27A1—atherosclerosis	5.7e-05	0.000462	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—AGT—atherosclerosis	5.69e-05	0.000462	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—LEP—atherosclerosis	5.68e-05	0.000461	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—APOE—atherosclerosis	5.68e-05	0.000461	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CG—atherosclerosis	5.67e-05	0.00046	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CAV1—atherosclerosis	5.62e-05	0.000456	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EDNRA—atherosclerosis	5.62e-05	0.000456	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCR2—atherosclerosis	5.62e-05	0.000456	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—APOA1—atherosclerosis	5.61e-05	0.000455	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GHRL—atherosclerosis	5.6e-05	0.000454	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PLAT—atherosclerosis	5.6e-05	0.000454	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PARP1—atherosclerosis	5.6e-05	0.000454	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CYBA—atherosclerosis	5.6e-05	0.000454	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—APOB—atherosclerosis	5.59e-05	0.000453	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—atherosclerosis	5.58e-05	0.000453	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CG—atherosclerosis	5.54e-05	0.00045	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PLAT—atherosclerosis	5.48e-05	0.000444	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GHRL—atherosclerosis	5.48e-05	0.000444	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PARP1—atherosclerosis	5.48e-05	0.000444	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ESR1—atherosclerosis	5.42e-05	0.00044	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PLA2G2A—atherosclerosis	5.4e-05	0.000438	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APOA2—atherosclerosis	5.4e-05	0.000438	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALOX15—atherosclerosis	5.4e-05	0.000438	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALOX5AP—atherosclerosis	5.4e-05	0.000438	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—F2—atherosclerosis	5.38e-05	0.000436	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—F2—atherosclerosis	5.35e-05	0.000434	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ABCG5—atherosclerosis	5.34e-05	0.000433	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—F2—atherosclerosis	5.26e-05	0.000427	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atherosclerosis	5.21e-05	0.000423	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—LPA—atherosclerosis	5.15e-05	0.000418	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CG—atherosclerosis	5.15e-05	0.000418	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CG—atherosclerosis	5.12e-05	0.000416	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CG—atherosclerosis	5.04e-05	0.000408	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—BGN—atherosclerosis	4.99e-05	0.000405	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APOA5—atherosclerosis	4.94e-05	0.000401	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—KNG1—atherosclerosis	4.92e-05	0.000399	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—MAPK3—atherosclerosis	4.91e-05	0.000398	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AGTR1—atherosclerosis	4.89e-05	0.000396	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—INS—atherosclerosis	4.85e-05	0.000393	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—KNG1—atherosclerosis	4.81e-05	0.00039	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CCL2—atherosclerosis	4.79e-05	0.000389	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AGTR1—atherosclerosis	4.78e-05	0.000388	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCL2—atherosclerosis	4.77e-05	0.000387	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PLG—atherosclerosis	4.76e-05	0.000386	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PLA2G1B—atherosclerosis	4.76e-05	0.000386	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—PPARA—atherosclerosis	4.71e-05	0.000382	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IGF1—atherosclerosis	4.69e-05	0.000381	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CCL2—atherosclerosis	4.69e-05	0.00038	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PLG—atherosclerosis	4.66e-05	0.000378	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALOX5—atherosclerosis	4.59e-05	0.000373	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SOCS3—atherosclerosis	4.51e-05	0.000366	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SERPINE1—atherosclerosis	4.45e-05	0.000361	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—APOA1—atherosclerosis	4.42e-05	0.000359	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SOCS3—atherosclerosis	4.41e-05	0.000358	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MMP3—atherosclerosis	4.36e-05	0.000353	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IGF2—atherosclerosis	4.34e-05	0.000352	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MMP3—atherosclerosis	4.26e-05	0.000346	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NOS3—atherosclerosis	4.25e-05	0.000345	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IGF2—atherosclerosis	4.24e-05	0.000344	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—APOB—atherosclerosis	4.21e-05	0.000342	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CXCL8—atherosclerosis	4.17e-05	0.000339	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EDN1—atherosclerosis	4.14e-05	0.000336	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NAMPT—atherosclerosis	4.12e-05	0.000334	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—APOB—atherosclerosis	4.12e-05	0.000334	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCL5—atherosclerosis	4.11e-05	0.000333	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—LIPC—atherosclerosis	4.1e-05	0.000332	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CXCL8—atherosclerosis	4.08e-05	0.000331	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APOC3—atherosclerosis	4.07e-05	0.00033	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EDN1—atherosclerosis	4.05e-05	0.000329	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—LDLR—atherosclerosis	4.05e-05	0.000328	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCL5—atherosclerosis	4.02e-05	0.000326	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—LPL—atherosclerosis	4.02e-05	0.000326	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CETP—atherosclerosis	3.95e-05	0.000321	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—LPL—atherosclerosis	3.93e-05	0.000319	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PRKCG—atherosclerosis	3.91e-05	0.000317	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	3.88e-05	0.000315	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PRKCG—atherosclerosis	3.82e-05	0.00031	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SPP1—atherosclerosis	3.81e-05	0.000309	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CXCL8—atherosclerosis	3.79e-05	0.000307	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SCARB1—atherosclerosis	3.78e-05	0.000307	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CXCL8—atherosclerosis	3.77e-05	0.000306	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SPP1—atherosclerosis	3.72e-05	0.000302	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CXCL8—atherosclerosis	3.71e-05	0.000301	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—AKT1—atherosclerosis	3.64e-05	0.000296	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—IL6—atherosclerosis	3.59e-05	0.000291	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—HMGCR—atherosclerosis	3.57e-05	0.00029	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PDGFB—atherosclerosis	3.52e-05	0.000286	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	3.5e-05	0.000284	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PDGFB—atherosclerosis	3.45e-05	0.00028	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AGT—atherosclerosis	3.44e-05	0.000279	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MMP9—atherosclerosis	3.41e-05	0.000277	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NFKB1—atherosclerosis	3.38e-05	0.000274	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—LEP—atherosclerosis	3.37e-05	0.000273	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—APOE—atherosclerosis	3.37e-05	0.000273	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AGT—atherosclerosis	3.36e-05	0.000273	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CAV1—atherosclerosis	3.34e-05	0.000271	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—APOA1—atherosclerosis	3.33e-05	0.00027	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MAPK8—atherosclerosis	3.32e-05	0.000269	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—AKT1—atherosclerosis	3.31e-05	0.000268	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—LEP—atherosclerosis	3.3e-05	0.000267	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—APOE—atherosclerosis	3.3e-05	0.000267	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CAV1—atherosclerosis	3.27e-05	0.000265	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—APOA1—atherosclerosis	3.26e-05	0.000264	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ESR1—atherosclerosis	3.22e-05	0.000261	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ABCA1—atherosclerosis	3.18e-05	0.000258	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—F2—atherosclerosis	3.18e-05	0.000258	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ESR1—atherosclerosis	3.15e-05	0.000255	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—F2—atherosclerosis	3.11e-05	0.000252	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—VEGFA—atherosclerosis	3.06e-05	0.000249	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CG—atherosclerosis	3.04e-05	0.000247	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—STAT3—atherosclerosis	3.03e-05	0.000246	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CG—atherosclerosis	2.97e-05	0.000241	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—MAPK3—atherosclerosis	2.91e-05	0.000236	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MAPK3—atherosclerosis	2.9e-05	0.000235	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—INS—atherosclerosis	2.88e-05	0.000234	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—MAPK3—atherosclerosis	2.85e-05	0.000231	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCL2—atherosclerosis	2.83e-05	0.00023	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—INS—atherosclerosis	2.82e-05	0.000228	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TGFB1—atherosclerosis	2.81e-05	0.000228	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IGF1—atherosclerosis	2.78e-05	0.000226	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCL2—atherosclerosis	2.77e-05	0.000225	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—HMOX1—atherosclerosis	2.73e-05	0.000222	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IGF1—atherosclerosis	2.72e-05	0.000221	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SERPINE1—atherosclerosis	2.64e-05	0.000214	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APOB—atherosclerosis	2.62e-05	0.000212	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SERPINE1—atherosclerosis	2.59e-05	0.00021	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTM1—atherosclerosis	2.55e-05	0.000207	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NOS3—atherosclerosis	2.52e-05	0.000205	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—LPL—atherosclerosis	2.5e-05	0.000203	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NOS3—atherosclerosis	2.47e-05	0.0002	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GPX1—atherosclerosis	2.44e-05	0.000198	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CD36—atherosclerosis	2.37e-05	0.000193	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—MTHFR—atherosclerosis	2.25e-05	0.000183	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CXCL8—atherosclerosis	2.24e-05	0.000182	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PPARA—atherosclerosis	2.21e-05	0.000179	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CXCL8—atherosclerosis	2.19e-05	0.000178	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—AKT1—atherosclerosis	2.16e-05	0.000175	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AGT—atherosclerosis	2.14e-05	0.000173	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL6—atherosclerosis	2.13e-05	0.000173	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL6—atherosclerosis	2.12e-05	0.000172	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—AKT1—atherosclerosis	2.12e-05	0.000172	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APOE—atherosclerosis	2.09e-05	0.00017	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL6—atherosclerosis	2.08e-05	0.000169	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CAV1—atherosclerosis	2.08e-05	0.000168	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APOA1—atherosclerosis	2.07e-05	0.000168	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MMP9—atherosclerosis	2.03e-05	0.000164	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NFKB1—atherosclerosis	2e-05	0.000163	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MMP9—atherosclerosis	1.98e-05	0.000161	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MAPK8—atherosclerosis	1.97e-05	0.00016	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—AKT1—atherosclerosis	1.96e-05	0.000159	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NFKB1—atherosclerosis	1.96e-05	0.000159	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AKT1—atherosclerosis	1.95e-05	0.000159	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MAPK8—atherosclerosis	1.93e-05	0.000156	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—AKT1—atherosclerosis	1.92e-05	0.000156	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CG—atherosclerosis	1.89e-05	0.000153	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PPARG—atherosclerosis	1.82e-05	0.000148	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—VEGFA—atherosclerosis	1.82e-05	0.000148	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—STAT3—atherosclerosis	1.8e-05	0.000146	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—INS—atherosclerosis	1.79e-05	0.000145	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—VEGFA—atherosclerosis	1.78e-05	0.000144	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—STAT3—atherosclerosis	1.76e-05	0.000143	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MAPK3—atherosclerosis	1.72e-05	0.00014	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MAPK3—atherosclerosis	1.68e-05	0.000137	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TGFB1—atherosclerosis	1.67e-05	0.000135	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALB—atherosclerosis	1.64e-05	0.000133	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TGFB1—atherosclerosis	1.63e-05	0.000132	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NOS3—atherosclerosis	1.57e-05	0.000127	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PTGS2—atherosclerosis	1.44e-05	0.000116	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL6—atherosclerosis	1.26e-05	0.000102	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL6—atherosclerosis	1.23e-05	9.98e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AKT1—atherosclerosis	1.16e-05	9.41e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AKT1—atherosclerosis	1.14e-05	9.21e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AKT1—atherosclerosis	7.21e-06	5.85e-05	CbGpPWpGaD
